Consistent with these observations, two different allosteric HIF2 inhibitors, belzutifan and NKT2152, rapidly ameliorated hypercalcemia and cachexia in patients with ccRCC, including in some who did not exhibit objective tumor shrinkage. Our findings support prospective clinical studies to determine whether HIF2 inhibitors can be leveraged not only for tumor control, but also for the treatment of cancer-associated cachexia in renal cell carcinoma.

16 days ago

Journal

PTHLH (Parathyroid Hormone Like Hormone)

Welireg (belzutifan) • NKT2152

24d

Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Other Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom (clinicaltrials.gov)

P1/2, N=139, Not yet recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd.

24 days ago

New P1/2 trial

Avastin (bevacizumab) • CS1002 (ipilimumab biosimilar) • AiRuiLi (adebrelimab) • NKT2152

NKT2152-101: A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma (clinicaltrials.gov)

P1/2, N=120, Terminated, NiKang Therapeutics, Inc. | Trial completion date: Sep 2026 --> Sep 2025 | Active, not recruiting --> Terminated | Trial primary completion date: May 2025 --> Aug 2025; This study was terminated as a result of Sponsor portfolio reprioritization.

1 month ago

Trial completion date • Trial termination • Trial primary completion date

PD-L1 (Programmed death ligand 1)

NKT2152

NKT2152-202: Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc) (clinicaltrials.gov)

P2, N=18, Terminated, NiKang Therapeutics, Inc. | N=172 --> 18 | Trial completion date: Jun 2026 --> Sep 2025 | Active, not recruiting --> Terminated; This study was terminated as a result of Sponsor portfolio reprioritization.

1 month ago

Enrollment change • Trial completion date • Trial termination

Ibrance (palbociclib) • sasanlimab (PF-06801591) • NKT2152

3ms

HIF2-driven PTHrP Causes Cachexia and Hypercalcemia in Kidney Cancer: Treatment with HIF2 Inhibitors. (PubMed, bioRxiv)

Further, we show that the increased PTHLH expression is both necessary and sufficient for the induction of hypercalcemia and cachexia in preclinical orthotopic cell line tumor models. Consistent with these observations, two different allosteric HIF2 inhibitors, belzutifan and NKT2152, rapidly ameliorated hypercalcemia and cachexia in ccRCC patients, including in some patients who did not exhibit objective tumor shrinkage.

3 months ago

Journal

PTHLH (Parathyroid Hormone Like Hormone)

Welireg (belzutifan) • NKT2152

4ms

Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell Carcinoma (clinicaltrials.gov)

P1/2, N=104, Recruiting, Jiangsu Hansoh Pharmaceutical Co., Ltd.

4 months ago

New P1/2 trial

Lenvima (lenvatinib) • NKT2152

5ms

Hypoxia Inducible Factor-2α (HIF-2α) Pathway Inhibitors. (PubMed, J Kidney Cancer VHL)

We discuss the major key inhibitors, with focus on belzutifan and review the various trials investigating its efficacy in monotherapy as well as in combination therapies in RCC...We also highlight emerging HIF-2α inhibitors currently in clinical trials, namely casdatifan, NKT-2152, and DFF332. Finally, we address the major toxicities and management of these inhibitors.

5 months ago

Review • Journal

VHL (von Hippel-Lindau tumor suppressor) • EPAS1 (Endothelial PAS domain protein 1) • CA9 (Carbonic anhydrase 9) • POU5F1 (POU Class 5 Homeobox 1) • ARNT (Aryl Hydrocarbon Receptor Nuclear Translocator)

Welireg (belzutifan) • DFF332 • NKT2152 • casdatifan (AB521)

1year

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) (clinicaltrials.gov)

P1/2, N=518, Recruiting, Hoffmann-La Roche | Trial completion date: Aug 2026 --> Dec 2026 | Trial primary completion date: Aug 2026 --> Dec 2026

1 year ago

Trial completion date • Trial primary completion date • Metastases

PD-L1 (Programmed death ligand 1)

Avastin (bevacizumab) • Tecentriq (atezolizumab) • amezalpat (TPST-1120) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • IO-108 • NKT2152 • muzastotug (ADG126) • tobemstomig (RG6139)

1year

NKT2152-202: Ph2 Study NKT2152 with Palbociclib & Sasanlimab in Subjects with Advanced Clear Cell Renal Cell Carcinoma (ccRcc) (clinicaltrials.gov)

P2, N=172, Active, not recruiting, NiKang Therapeutics, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Sep 2026 --> Jun 2026 | Trial primary completion date: Jun 2026 --> Jun 2025

1 year ago

Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy • Metastases

Ibrance (palbociclib) • sasanlimab (PF-06801591) • NKT2152

1year

NKT2152-101: A Study of NKT2152, a HIF2α Inhibitor, in Patients with Advanced Clear Cell Renal Cell Carcinoma (clinicaltrials.gov)

P1/2, N=128, Active, not recruiting, NiKang Therapeutics, Inc. | Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2024 --> May 2025

1 year ago

Enrollment closed • Trial primary completion date • Metastases

PD-L1 (Programmed death ligand 1)

NKT2152

over1year

A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors (clinicaltrials.gov)

P1, N=60, Recruiting, Jiangsu Hansoh Pharmaceutical Co., Ltd.

over 1 year ago

New P1 trial

NKT2152

over1year

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) (clinicaltrials.gov)

P1/2, N=506, Recruiting, Hoffmann-La Roche | Trial completion date: Dec 2025 --> Aug 2026 | Trial primary completion date: Dec 2025 --> Aug 2026

over 1 year ago

Trial completion date • Trial primary completion date

PD-L1 (Programmed death ligand 1)

Avastin (bevacizumab) • Tecentriq (atezolizumab) • amezalpat (TPST-1120) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • NKT2152 • muzastotug (ADG126) • tobemstomig (RG6139)